Indivior Pharmaceuticals has delivered four consecutive earnings beats with an average positive surprise exceeding 60%, trades at a forward price-to-earnings ratio of 9.8x with a PEG of 0.12, and carries best-in-class peer-relative margins — a combination of execution and valuation that makes the risk/reward favorable at current levels, tempered by a cash-conversion gap and 13% short interest that warrant ongoing monitoring.
Thesis pillars
- Best In Class Peer Margins↓Deteriorating
- Perfect Four Quarter Beat Streak→Stable
- Attractive Valuation Low Peg→Stable
- +2 more pillars — see the Why tab for full reasoning
Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $36.00, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak.
Indivior Pharmaceuticals markets two FDA-approved opioid use disorder treatments — SUBLOCADE (monthly buprenorphine injection, $856 million global net sales in 2025) and SUBOXONE Film ($346 million) — with 85% of net revenues generated in the U.S. SUBLOCADE accounted for 69% of... Read more
Hold if already holding. Not a fresh buy at $36.00, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.3/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 40d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About Indivior Pharmaceuticals, Inc.
About Indivior Pharmaceuticals, Inc.
SUBLOCADE, Indivior Pharmaceuticals' monthly injectable buprenorphine for opioid use disorder, generated $856 million in global net sales in 2025 — 69% of total net revenues, up from 64% in 2024. SUBOXONE Film contributed $346 million in global net sales. The U.S. accounted for 85% of net revenues in both 2025 and 2024. The FDA granted SUBLOCADE a label expansion on February 24, 2025, adding rapid initiation and alternative injection sites.
Indivior generates revenue through prescription sales of SUBLOCADE and SUBOXONE Film, with SUBLOCADE distributed through a closed specialty pharmacy network using a REMS protocol that prevents patients from taking direct possession of the drug. Over 88% of U.S. insured lives have SUBLOCADE coverage and more than 95% of patients enrolled in the co-pay program paid zero out of pocket in 2025. Revenues from SUBOXONE Film are declining: under a 2020 Department of Justice Resolution Agreement, the company may not employ a sales force to promote SUBOXONE Film in the U.S., and a separate opioid MDL settlement restricts marketing through 2032. The company completed its obligations under the Resolution Agreement, including $600 million in total payments, in November 2025. Outside the U.S., Indivior sells products in Canada, Australia, France, and Germany, having exited the U.K., Ireland, Sweden, Israel, Finland, and Italy in October 2025.
Show full overview
Indivior's manufacturing relies almost exclusively on third-party contract manufacturers for sterile fill and finished-dose production. The 10-K discloses that the company relies on either a single or dual source of supply for raw materials, product components, and APIs for most marketed products, including buprenorphine. Technology transfer to a new supplier averages 36 months per the filing and requires separate FDA approval of any new manufacturing site, meaning a supply disruption at a primary CMO could affect commercial availability for multiple years. Any delay could also violate contractual delivery obligations.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Indivior Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-09-25Recent Developments — Indivior Pharmaceuticals, Inc.
Latest news
- NEWS INDV|Indivior PLC|Price:40.970|Chg%:+0.940 - TradingKey — TradingKey neutral
- NEWS Indivior PLC (INDV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey — TradingKey neutral
- NEWS Indivior PLC (INDV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com — tradingkey.com neutral
- NEWS Indivior Pharmaceuticals stock reports USD 8.13 special dividend - AD HOC NEWS — AD HOC NEWS positive
- NEWS Indivior Pharmaceuticals stock reports USD 8.13 special dividend - ad-hoc-news.de — ad-hoc-news.de positive
Generated 2026-09-26T04:01:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $36.00, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $41.65 (+15.7%), stop $34.14 (−5.4%), A.R:R 2.5:1. Score 6.3/10, moderate confidence.
Take-profit target: $41.65 (+15.7% upside). Target $41.65 (+15.7%), stop $34.14 (−5.4%), A.R:R 2.5:1. Stop-loss: $34.14.
Indivior Pharmaceuticals, Inc. trades at a P/E of 12.9 (forward 7.4). TrendMatrix value score: 8.6/10. Verdict: Hold.
10 analysts cover INDV with a consensus score of 4.2/5. Average price target: $49.
What does Indivior Pharmaceuticals, Inc. do?Indivior Pharmaceuticals markets two FDA-approved opioid use disorder treatments — SUBLOCADE (monthly buprenorphine...
Indivior Pharmaceuticals markets two FDA-approved opioid use disorder treatments — SUBLOCADE (monthly buprenorphine injection, $856 million global net sales in 2025) and SUBOXONE Film ($346 million) — with 85% of net revenues generated in the U.S. SUBLOCADE accounted for 69% of total net revenues in 2025, distributed through a closed specialty pharmacy network.